EYLEA Drug Profile

Summary for Tradename: EYLEA

High Confidence Patents:	56
Applicants:	1
BLAs:	2

Pharmacology for EYLEA

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EYLEA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EYLEA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,130,681	2037-03-28	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,182,969	2036-03-10	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,464,992	2038-10-12	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,828,345	2038-10-12	DrugPatentWatch analysis and company disclosures
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,857,205	2038-08-06	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for EYLEA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,004,788	2037-12-21	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,047,096	2035-11-23	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,077,280	2036-11-15	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,086,010	2035-03-17	Patent claims search
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	10,093,689	2038-05-25	Patent claims search

International Patents for EYLEA

Country	Patent Number	Estimated Expiration
Chile	2023002512
Spain	2323468
Malaysia	193353
Australia	2016228990
Israel	318471

Supplementary Protection Certificates for EYLEA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
500	Finland
132013902154380	Italy		PRODUCT NAME: AFLIBERCEPT(EYLEA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/797/001-002, 20121122
C201300026	Spain		PRODUCT NAME: AFLIBERCEPT; NATIONAL AUTHORISATION NUMBER: EU/1/12/797/001-002; DATE OF AUTHORISATION: 20121122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/797/001-002; DATE OF FIRST AUTHORISATION IN EEA: 20121122
20/2013	Austria		PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/797/001 UND 002 20121122
1390020-4	Sweden		PRODUCT NAME: AFLIBERCEPT; REG. NO/DATE: EU/1/12/797/001 20121122

Market Dynamics and Financial Trajectory for EYLEA

Last updated: April 22, 2026

EYLEA (aflibercept) is a monoclonal antibody fusion protein developed by Regeneron Pharmaceuticals. It is approved for the treatment of various retinal vascular diseases, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR). It has become a leading product in the ophthalmology biologics segment.

Market Size and Growth Drivers

As of 2022, global sales of EYLEA exceeded $8 billion. Sales grew at a compound annual growth rate (CAGR) of approximately 10% from 2016 to 2021, reflecting expanding indications, geographic expansion, and increased penetration in existing markets.

Key growth drivers include:

• Aging population: The prevalence of AMD and diabetic eye diseases rises with age.
• Technological advantage: EYLEA’s dosing schedule—initial monthly injections followed by bimonthly maintenance—reduces treatment burden versus competitors like Lucentis (ranibizumab).
• Brand loyalty: Physicians favor EYLEA for its efficacy and dosing flexibility.
• Geographic expansion: Steady entry into emerging markets, particularly China, South Korea, and Latin America.

Competitive Landscape

Major competitors include:

Drug	Manufacturer	Indications	Pricing (per injection)	Market Share (2022)
EYLEA	Regeneron	AMD, DME, PDR	$1,800–$2,200	55%
Lucentis	Roche/Novartis	AMD, DME	$1,850–$2,300	30%
Beovu	Bayer	AMD	$1,900–$2,350	10%
Faricimab	Roche (phase 3 stage)	AMD, DME (in development)	Pending approval	Rising (potential to capture market share)

EYLEA maintains dominant market share, owing to clinical confidence and longer dosing intervals.

Regulatory and Indication Expansion

Regulatory approvals have expanded EYLEA’s applications:

• US FDA (2011): Approved for wet AMD.
• Europe EMA (2012): Approved for wet AMD.
• Japan PMDA (2012): Approved for AMD and DME.
• India DCGI (2014): Approved for diabetic retinopathy.

In 2022, regulatory filings expanded EYLEA’s indication to include treatment of polypoidal choroidal vasculopathy. The expanded label should support revenue growth and patient access.

Revenue Projections and Financial Trajectory

Regeneron reports EYLEA revenues separately from other products. The financial outlook relies on:

• Sales growth estimates: 8-10% CAGR through 2026.
• Pricing trends: Slight reductions due to biosimilar pressure and market access negotiations.
• Volume growth: Driven by new patient initiation and increased treatment frequency in emerging markets.

Financial Estimates (2022–2026)

Year	Revenue (USD billion)	Growth Rate	Comments
2022	8.2	—	Baseline, established market dominance
2023	8.9	8.5%	Expansion into new indications, price adjustments
2024	9.7	9%	Market penetration increases, emerging markets growth
2025	10.5	8%	Potential biosimilar entry pressure, continued growth
2026	11.3	8%	Mature growth, sustained uptake

Risks to Financial Trajectory

• Biosimilar Competition: Examples like Samsung Bioepis’ biosimilar for EYLEA in development threaten pricing power.
• Regulatory delays: Approval of new indications or biosimilars could affect sales.
• Market saturation: Penetration rates have plateaued in mature markets.

Strategic Considerations

• Pipeline development: Regeneron’s pipeline includes newer agents, such as bispecific antibodies, aiming to extend market share.
• Pricing strategies: Regulatory and payor pressures necessitate competitive pricing.
• Geographic expansion: Accelerating market access in Asia, especially China, offers growth opportunities.

Conclusion

EYLEA remains a cornerstone of retinal disease therapy with steady revenue growth driven by expanding indications and geographic reach. Market share is stable amid biosimilar threats, but continued innovation and geographic penetration are critical to sustaining trajectory.

Key Takeaways

• EYLEA’s 2022 sales exceeded $8 billion, with an expected CAGR of around 8-10% through 2026.
• Market dominance stems from dosing convenience, efficacy, and geographic expansion.
• Biosimilar competition emerges in the next 2-3 years, posing pricing and market share risks.
• Regulatory expansion broadens indications, supporting future growth.
• Emerging markets hold significant potential due to rising prevalence of retinal diseases.

FAQs

Q1: What factors sustain EYLEA’s market dominance?
A1: Clinical efficacy, flexible dosing schedule, physician familiarity, and expanding regulatory approvals.

Q2: How does biosimilar competition impact EYLEA’s financial outlook?
A2: Biosimilars could lower prices and erode market share, potentially limiting revenue growth from 2024 onward.

Q3: Which emerging markets are key for future growth?
A3: China, India, Brazil, and Southeast Asian countries.

Q4: Are there any recent regulatory approvals affecting EYLEA?
A4: In 2022, approval was granted for the treatment of polypoidal choroidal vasculopathy, expanding its indication.

Q5: How does EYLEA compare with its closest competitor, Lucentis?
A5: EYLEA generally offers longer dosing intervals, which improves patient compliance and reduces healthcare costs, maintaining a slight edge in market preference.

---

References

1. Regeneron Pharmaceuticals. (2022). EYLEA product pipeline and sales data.
2. IQVIA. (2022). Global ophthalmology therapeutics report.
3. U.S. Food & Drug Administration. (2011). EYLEA approval documents.
4. European Medicines Agency. (2012). EYLEA summary of product characteristics.
5. ClinicalTrials.gov. (2022). EYLEA indication expansion studies.